Blocking Somatostatin Receptor-2 Improves Steroid-Induced Muscle and Bone Wasting in Rats
A somatostatin-2 receptor antagonist (BIM-23627) improved the catabolic effects of chronic glucocorticoid treatment in rats, partially restoring GH signaling and reducing muscle/bone wasting.
Quick Facts
What This Study Found
Somatostatin subtype-2 receptor antagonist BIM-23627 partially reversed glucocorticoid-induced catabolism in rats by reducing somatostatin's GH-inhibitory tone, improving GH/IGF-1 axis activity and reducing muscle and bone loss from chronic steroids.
Key Numbers
How They Did This
animal-study study on neuropeptides, hormone-optimization.
Why This Research Matters
Relevant for neuropeptides, hormone-optimization.
The Bigger Picture
Advances peptide/biomarker research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding Somatostatin subtype-2 receptor antagonist BIM-23627 partially reversed glucocorticoid-induced catabolism in rats by reducing somatostatin's GH-inhibi
- Evidence Grade:
- preliminary evidence.
- Study Age:
- Published in 2005.
- Original Title:
- The somatostatin subtype-2 receptor antagonist, BIM-23627, improves the catabolic effects induced by long-term glucocorticoid treatment in the rat.
- Published In:
- Regulatory peptides, 125(1-3), 85-92 (2005)
- Authors:
- Tulipano, Giovanni(3), Rossi, Elena, Culler, Michael D(4), Taylor, John E, Bonadonna, Stefania, Locatelli, Vittorio, Cocchi, Daniela, Giustina, Andrea
- Database ID:
- RPEP-01094
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What was studied?
Blocking Somatostatin Receptor-2 Improves Steroid-Induced Muscle and Bone Wasting in Rats
What was found?
A somatostatin-2 receptor antagonist (BIM-23627) improved the catabolic effects of chronic glucocorticoid treatment in rats, partially restoring GH signaling and reducing muscle/bone wasting.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01094APA
Tulipano, Giovanni; Rossi, Elena; Culler, Michael D; Taylor, John E; Bonadonna, Stefania; Locatelli, Vittorio; Cocchi, Daniela; Giustina, Andrea. (2005). The somatostatin subtype-2 receptor antagonist, BIM-23627, improves the catabolic effects induced by long-term glucocorticoid treatment in the rat.. Regulatory peptides, 125(1-3), 85-92.
MLA
Tulipano, Giovanni, et al. "The somatostatin subtype-2 receptor antagonist, BIM-23627, improves the catabolic effects induced by long-term glucocorticoid treatment in the rat.." Regulatory peptides, 2005.
RethinkPeptides
RethinkPeptides Research Database. "The somatostatin subtype-2 receptor antagonist, BIM-23627, i..." RPEP-01094. Retrieved from https://rethinkpeptides.com/research/tulipano-2005-the-somatostatin-subtype2-receptor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.